Broadfin Capital’s Pacira BioSciences PCRX Stock Holding History

Broadfin Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-166,500	Closed	-$5.19M	–	54
2018 Q1	$5.19M	Buy	+166,500	New	+$5.93M	0.81%	35
2017 Q1	–	Sell	-150,680	Closed	-$4.87M	–	59
2016 Q4	$4.87M	Hold	150,680	–	–	0.54%	42
2016 Q3	$5.16M	Buy	150,680 +57,300	+61%	+$2.24M	0.46%	53
2016 Q2	$3.15M	Buy	+93,380	New	+$4.59M	0.31%	57

Other funds holding PCRX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Broadfin Capital's PCRX Position: Q2 2018 in Review

Broadfin Capital sold out of Pacira BioSciences (PCRX) in Q2 2018, closing a stake of 166,500 shares — an estimated $5.19M sold.

Broadfin Capital first reported a position in PCRX in Q2 2016 and held it in 4 quarters. The position peaked at $5.19M in Q1 2018. 156 funds tracked by Wall St. Rank hold PCRX as of Q2 2018.

Broadfin Capital reported no remaining Pacira BioSciences position as of Q2 2018 after selling out during the quarter.
Broadfin Capital sold 166,500 Pacira BioSciences shares in Q2 2018, an estimated $5.19M.
Broadfin Capital first reported a position in Pacira BioSciences in Q2 2016 and held it in 4 quarters.
Broadfin Capital's Pacira BioSciences position peaked at $5.19M in Q1 2018.
156 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2018.

Based on Broadfin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.